News18 » Videos » News18 Shorts

COVID-19| India’s Top Drug Regulator Questions Glenmark On FabiFlu's Pricing, Effectiveness

Jul 20, 2020 08:43 PM IST India India
Share

Glenmark Pharmaceuticals have been asked for a clarification by the Drugs Controller General of India (DCGI). DCGI VG Somani sent a letter to Glenmark seeking clarification on alleged “false claim” on the utilisation of FabiFlu or Favipiravir on COVID-19 patients with comorbidities. DCGI has also asked for an explanation on the pricing of the drug.

Loading